Multidrug-resistant Gram-negative bacteria: Difference between revisions
From IDWiki
(Created page with "== Management == * Ceftolozane-tazobactam ** * Ceftazidime-avibactam ** Special Access Program * Fosfomycin ** * Colistin ** * Cefiderocol ** Special A...") |
No edit summary |
||
| Line 1: | Line 1: | ||
== |
==Management== |
||
* |
*[[Ceftolozane-tazobactam]] (Zerbaxa) |
||
| ⚫ | |||
* |
|||
* [[Ceftazidime-avibactam]] |
|||
** Special Access Program |
|||
*[[Ceftazidime-avibactam]]: available through Special Access Program |
|||
* |
*[[Fosfomycin]] |
||
| ⚫ | |||
| ⚫ | |||
* |
*[[Colistin]] |
||
** |
|||
| ⚫ | |||
* [[Cefiderocol]] |
|||
* |
*[[Cefiderocol]]: available through Special Access Program as well as preapproval by manufacturer |
||
* |
*[[Meropenem-vaborbactam]]: still awaiting Health Canada Drug Review |
||
* |
*[[Imipenem-relebactam]] (really imipenem-cilastatin-relebactam): still awaiting Health Canada Drug Review |
||
* [[Imipenem-relebactam]] |
|||
** Really imipenem-cilastatin-relebactam |
|||
** Awaiting Health Canada Drug Review |
|||
Revision as of 13:29, 26 August 2020
Management
- Ceftolozane-tazobactam (Zerbaxa)
- Ceftazidime-avibactam: available through Special Access Program
- Fosfomycin
- Colistin
- Cefiderocol: available through Special Access Program as well as preapproval by manufacturer
- Meropenem-vaborbactam: still awaiting Health Canada Drug Review
- Imipenem-relebactam (really imipenem-cilastatin-relebactam): still awaiting Health Canada Drug Review
References
- ^ A.-P. Magiorakos, A. Srinivasan, R.B. Carey, Y. Carmeli, M.E. Falagas, C.G. Giske, S. Harbarth, J.F. Hindler, G. Kahlmeter, B. Olsson-Liljequist, D.L. Paterson, L.B. Rice, J. Stelling, M.J. Struelens, A. Vatopoulos, J.T. Weber, D.L. Monnet. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical Microbiology and Infection. 2012;18(3):268-281. doi:10.1111/j.1469-0691.2011.03570.x.
